" class="no-js "lang="en-US"> Fabrice Viviani - Medtech Alert
Tuesday, August 05, 2025
Fabrice Viviani

Fabrice Viviani

About Fabrice Viviani

Fabrice Viviani holds a PhD in organic chemistry and an MA in biology from Pierre-and-Marie-Curie University (UPMC). He started his career as a biologist and was responsible for research project and clinical teams in infectiology, before turning his attention to oncology research at Aventis’ oncology therapy department. He was then appointed Sanofi-Aventis’ Vice President for R&D, having managed several departments (medicinal chemistry and biology for exploratory research and internal medicine, early-to-candidate DPU). At GSK he took charge of the discovery biology group at the François Hyafil research center. To date, he has been involved in discovering and developing over 20 preclinical and clinical drug candidates.

Related Story

Abzena, Alira Health and Oncodesign Launch DRIVE™-Biologics to Support Access to Specialist Services from Discovery to Clinical Development for Oncology and Inflammation

February 25 2022

Abzena, a partner research organization for integrated services from discovery through to clinical and commercial […]

Oncodesign, Covalab, CheMatech and ABX-CRO Launch DRIVE™-MRT, a Premium Complete, Integrated Service Offer for Radiopharmaceuticals Drug Discovery and Generation

July 2 2021

ONCODESIGN (ALONC -FR0011766229), a French biopharmaceutical company dedicated to precision medicine, Covalab (Bron, France), a biotechnology company specializing […]